000			02288 a2200613 4500
005			20250514073416.0
264		0	_c20030814
008			200308s 0 0 eng d
022			_a0732-183X
024	7		_a10.1200/JCO.2003.07.127 _2doi
040			_aNLM _beng _cNLM
100	1		_aAltorki, N K
245	0	0	_aCelecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. _h[electronic resource]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJul 2003
300			_a2645-50 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aCelecoxib
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aCyclooxygenase Inhibitors _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aPneumonectomy
650	0	4	_aPreoperative Care _xmethods
650	0	4	_aPyrazoles
650	0	4	_aSulfonamides _xadministration & dosage
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aKeresztes, R S
700	1		_aPort, J L
700	1		_aLibby, D M
700	1		_aKorst, R J
700	1		_aFlieder, D B
700	1		_aFerrara, C A
700	1		_aYankelevitz, D F
700	1		_aSubbaramaiah, K
700	1		_aPasmantier, M W
700	1		_aDannenberg, A J
773	0		_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 21 _gno. 14 _gp. 2645-50
856	4	0	_uhttps://doi.org/10.1200/JCO.2003.07.127 _zAvailable from publisher's website
999			_c12641135 _d12641135